Clinical Trial Details
— Status: Active, not recruiting
Administrative data
| NCT number |
NCT05395897 |
| Other study ID # |
RC21_0409 |
| Secondary ID |
|
| Status |
Active, not recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
January 1, 2023 |
| Est. completion date |
December 13, 2024 |
Study information
| Verified date |
April 2024 |
| Source |
Nantes University Hospital |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
The health crisis linked to the coronavirus has had a significant impact on the mental
health. The question of the repercussion of this crisis on the consumption of psychotropic
drugs is crucial. It is all the more true in France, which was already among the countries
with the highest consumption of psychotropic drugs before the crisis. Indeed, an increase in
the number of reimbursements for anxiolytic, hypnotic and antidepressant drugs has been
highlighted in the context of the health crisis, using data from the health insurance
database.
To enhance the understanding about the impacts of the health crisis on the use of
psychotropic drugs, it is essential to characterize the evolution of the use at the
individual level.
The main objective is to assess the impact of the coronavirus-related health crisis on the
consumption of psychotropic drugs by studying the trajectories of reimbursements.
The secondary objective of the project is to evaluate the evolution of problematic
consumption of psychotropic drugs in the context of the health crisis.
Description:
The project will allow studying the evolution of the use of psychotropics since the
coronavirus-related health crisis according to the temporality of consumption (succession
and/or concomitance of consumption) or their persistence over time.
This project has two major aims:
- Pharmacosurveillance: evaluation of the impact of psychotropic drug consumption in the
context of the health crisis related to the coronavirus. The consumption of psychotropic
drugs is a public health issue in France and concerns the entire general population.
Even before the crisis, France was one of the countries in the world where the
consumption of psychotropic drugs was the highest.
- Scientific: use of an innovative methodology for assessing the impact of
pharmaco-epidemiology (trajectories based on reimbursement data).
